pharmaceuticals
To sponsor this category, click here | subscribe to this category RSS

Aveo Pharma delays IPO, at least briefly

Thursday, March 11th, 2010

Aveo Pharmaceuticals kept the biotech investment community on pins and needles this morning.

Read the full story

BioSante shares surge as cancer vax performs in small study

Thursday, March 11th, 2010

Shares of BioSante Pharmaceuticals surged this morning in pre-market trading after the developer said that a 19-patient study demonstrated the promise of its GVAX leukemia vaccine to mop up the stubbornly lingering cancer cells of CML patients taking Gleevec. Researchers said that the 19 patients selected for

Read the full story

Who’s the next biotech buyout target?

Tuesday, March 9th, 2010

With Astellas Pharma and OSI Pharmaceuticals haggling over price, BNet Pharma wonders which biotechs could be next on the buyout menu.

Read the full story

Alnara rises from Altus’ ashes

Friday, March 5th, 2010

Just 16 months after raising $20 million in its first round of funding, Massachusetts-based Alnara Pharmaceuticals

Read the full story

OSI shares soar as Astellas brawls over rejected bid

Tuesday, March 2nd, 2010

Astellas’ hostile bid to acquire OSI Pharmaceuticals –along with its

Read the full story

Astellas makes $3.5B hostile bid for OSI

Monday, March 1st, 2010

Astellas Pharma announced today that it has made a $3.5 billion

Read the full story

Anthera delays IPO and sends a chilling message

Thursday, February 25th, 2010

Biotech companies eager to dust off their old IPO plans may want to wait awhile longer. Anthera Pharmaceuticals, a classic drug developer with high hopes and no steady income, opted to delay its initial public offering yesterday rather than brave the chilly investment scene. The underwriters didn’t say exactly what was holding them back from their plan to sell 4.61 million shares at $13 to $15 a share

Read the full story

Salix braces for harsh panel review of Xifaxan

Tuesday, February 23rd, 2010

Salix Pharmaceuticals is headed for its scheduled showdown today with a panel of FDA experts who are expected to grill the company on Xifaxan (rifaximin), a drug that is being prepped for the hepatic encephalopathy market.

Read the full story

Tioga raises $18M for Phase III clinical trial

Wednesday, February 17th, 2010

San Diego-based Tioga Pharmaceuticals has rounded up $18 million to fund a late-stage trial which will enroll 600 patients with

Read the full story